Asia Insurance Review
China-Outbound/U.S.-Inbound M&A
July 2017
With the recent failed attempt by Anbang to obtain the required U.S. regulatory approvals to purchase Fidelity & Guaranty Life, this article provides insight into the U.S. insurance regulatory approval process and how Chinese and other foreign acquirers can navigate them successfully.
This article was first published in the July issue of Asia Insurance Review.
Contacts
Capabilities
Suggested News & Insights
Bad Investments, Not Bad Faith: Caremark Claims Have LimitsApril 21, 2026Sidley Represents Opus Genetics in US$155 Million Financing With Oberland CapitalApril 21, 2026Sidley Represents Galera Therapeutics in Its Merger With Obsidian Therapeutics and US$350 Million Private Placement FinancingApril 21, 2026Del. Ruling Shows Power of Postclose Governance Provisions in Earnout Disputes and Generative AI RiskApril 20, 2026Sidley Represents The Denver Post in Sale of Interest in Colorado RockiesApril 20, 2026Drinks With The Deal: Sidley’s Mehdi KhodadadApril 17, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory
